arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

GRI Bio, Inc.

GRI

$1.61 ▲ +0.06 (+3.87%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

GRI Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -157.5% ↗

FCF / Share —

Trailing P/E —

Price / Book 0.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-11.96M

↓ -45.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	92.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	98.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	9.1% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	91.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-32.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-45.7% Weak ↑ Weak Improving Year-over-year change in net income	37.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-305.3% Weak ↓ Weak Declining Year-over-year change in net income	65.4% Excellent Excellent Year-over-year change in net income	-92.9% Weak Weak Year-over-year change in net income	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.34x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-157.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-161.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-3473.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	108.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-125.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	260.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-138.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-143.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-385.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-584.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-111.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-501.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-199.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1427%)	-203.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1457%)	—	198.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1220%)	-159.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1166%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	-67.85x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-319.28x Weak Weak Operating income divided by interest expense Optimal: > 5x	-116.78x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-8.23M	$-5.03M	$-1.81M	$-9.00K	$-3.70M	$-109.00K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	—	—	$0.00	—	—
Basic EPS, GAAP (USD)	$-121.80	$-1.55K	$-140.56K	$-154.56K	$-1.85M	$-1.39M	—
Book Value per Share (USD)	$12.07	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$12.07	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	98,162	6,547	93	21	5	3	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$5.95M	$3.98M	$237.00K	$-1.68M	$5.68M	$-1.55M	—
Total Equity (USD)	$6.01M	$4.03M	$259.00K	$-1.62M	$5.82M	$-1.45M	$3.21M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	$0.00	$100.00K	—
Depreciation Expense (USD)	$4.00K	$4.00K	$4.00K	$3.00K	—	—	—
Net Income, GAAP (USD)	$-11.96M	$-8.21M	$-13.04M	$-3.22M	$-9.30M	$-4.82M	—
Operating Cash Flow (USD)	$-10.19M	$-8.61M	$-8.99M	$-1.08M	$-8.31M	$-3.71M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

GRI Bio, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare GRI with peers